Summary by Moomoo AI
Tengsheng Bo Pharmaceutical Biotechnology Co., Ltd. announced that its two investigational hepatitis B (HBV) treatment drugs BRII-877 (tobevibart) and BRII-835 (elebsiran) have been included as a breakthrough treatment strain by the China National Drug Administration Drug Review Center. This follows the company's breakthrough therapeutic strain recognition of BRII-179, another HBV treatment drug, obtained in November 2023, marking important progress in the field of HBV functional cure research. BRII-877 is based on Phase 1 and Phase 2 studies in collaboration with Vir Biotechnology, Inc., in which 350 patients have received treatment and demonstrated good tolerability and potential to reduce HBV surface antigen levels. BRII-835 demonstrated good tolerability and direct antiviral activity in more than 570 HBV infected patients. The company and its partner Vir plan to launch several joint studies in 2024 to optimize treatment options and provide better treatment options for HBV patients. The Company reminds shareholders and potential investors that these therapies are not yet guaranteed to be successfully developed or marketed, so caution should be exercised when investing.
